Combined Use of Stimulant and Non-Stimulant Medications for ADHD
Stimulant and non-stimulant medications can be safely combined in ADHD treatment, with extended-release guanfacine and extended-release clonidine being the only FDA-approved adjunctive therapies to stimulants, though atomoxetine can also be used in combination with careful monitoring. 1, 2
Approved Combinations and Evidence
- Extended-release guanfacine and extended-release clonidine are specifically FDA-approved "as adjunctive therapy to stimulant medications" to enhance treatment effects and/or decrease stimulant adverse effects 2, 3
- Atomoxetine can be safely used with stimulants as part of a combination approach, though this is considered off-label use 3, 4
- Combination therapy has shown significant improvement in ADHD symptoms compared to monotherapy in clinical studies 4
Benefits of Combination Therapy
- Stimulants provide rapid symptom control with large effect sizes, while non-stimulants offer complementary benefits 3, 5
- Non-stimulants can provide continuous 24-hour coverage, including morning and evening symptom control 3, 6
- Alpha-agonists (clonidine/guanfacine) can counteract stimulant-induced insomnia when given at bedtime 7
- Combination therapy may help reduce stimulant-related side effects such as sleep disturbances and cardiovascular effects 2
Specific Combination Strategies
Methylphenidate + Alpha-Agonists
- Start with a half clonidine tablet (0.05 mg) at bedtime and increase slowly, never exceeding 0.3 mg/day 7
- Clonidine can be given at bedtime for sleep or 4 times daily for aggressive behavior control 7
- Before starting clonidine, obtain a full medical history of the patient and first-degree family members 7
- A history of sudden death, repeated fainting, or arrhythmias in family members would contraindicate alpha-agonist use 7
Methylphenidate + Atomoxetine
- Atomoxetine can be administered once daily or split into two doses to reduce side effects 2, 6
- Monitor for additive cardiovascular effects, though these are typically minimal 1, 3
- This combination has shown enhanced effectiveness over monotherapy in clinical studies 4
Safety Considerations
- Routine ECG monitoring during treatment with stimulant and alpha-agonist combinations is not advised based on largely negative findings 7
- The rate of side effects such as bradycardia, hypotension, and hypertension with alpha-agonist combinations appears to be rare (less than 1/100) 7
- Common side effects of combined therapy include irritability (41.6%), appetite reduction (25%), palpitations (16.7%), and headache (8.3%) 4
- Atomoxetine has fewer and less pronounced adverse effects compared to alpha-agonists, making it better tolerated in most patients 3
Contraindications and Cautions
- Patients on MAO inhibitors should not be given stimulants due to risk of hypertensive crisis 7
- A case report of a child who died of cardiac arrhythmia while being treated with dextroamphetamine and high-dose imipramine (6.9 mg/kg/day) suggests caution with tricyclic antidepressant combinations 7
- SSRIs may be added to methylphenidate for treating comorbid depression, with no significant interactions reported 7
- There are no studies of the combination of bupropion and stimulants; proceed with caution until further studies are available 7
Monitoring Recommendations
- Once a child with ADHD is stabilized on medication, schedule visits once a month 7
- Use standardized rating scales to assess symptoms before initiating treatment and after each major dose adjustment 7
- Monitor vital signs in patients receiving stimulant treatment, as they can increase heart rate and blood pressure 1
- For combination therapy, more frequent monitoring may be necessary initially to assess for additive side effects 4